{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:06:24Z","timestamp":1794636384409,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72059-7","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:23:51Z","timestamp":1776979431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase \u2161 trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Liying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-2954","authenticated-orcid":false,"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8583-8595","authenticated-orcid":false,"given":"Yanfeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-5069","authenticated-orcid":false,"given":"Shuqiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5135-7891","authenticated-orcid":false,"given":"Kaihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3182-9191","authenticated-orcid":false,"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7048","authenticated-orcid":false,"given":"Guoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"72059_CR1","doi-asserted-by":"publisher","first-page":"S877","DOI":"10.1016\/j.annonc.2024.08.1466","volume":"35","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. 1400O final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G\/GEJ adenocarcinoma. Ann. Oncol. 35, S877\u2013S878 (2024).","journal-title":"Ann. Oncol."},{"key":"72059_CR2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2025.43.4_suppl.398","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian, Y. Y. et al. Nivolumab (NIVO)\u2009+\u2009chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 5-year (y) follow-up results from CheckMate 649. J. Clin. Oncol. 43, 398\u2013398 (2025).","journal-title":"J. Clin. Oncol."},{"key":"72059_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani, J. A. et al. Gastric Cancer, Version 2.2025, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 23, 169\u2013191 (2025).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"72059_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.  Lancet Oncol. 25, 212\u2013224 (2024).","journal-title":"Lancet Oncol."},{"key":"72059_CR5","doi-asserted-by":"publisher","first-page":"LBA246","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA246","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. J. Clin. Oncol. 42, LBA246 (2024).","journal-title":"J. Clin. Oncol."},{"key":"72059_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2024","unstructured":"Li, C. et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J. Clin. Oncol. 43, 464\u2013474 (2024).","journal-title":"J. Clin. Oncol."},{"key":"72059_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","volume":"30","author":"S-Q Yuan","year":"2024","unstructured":"Yuan, S.-Q. et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat. Med. 30, 552\u2013559 (2024).","journal-title":"Nat. Med."},{"key":"72059_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian, Y. Y. et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N. Engl. J. Med. 393, 217\u2013230 (2025).","journal-title":"N. Engl. J. Med."},{"key":"72059_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J. Clin. Oncol. 41, 255\u2013265 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72059_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1200\/JCO.2023.41.4_suppl.358","volume":"41","author":"F Pietrantonio","year":"2023","unstructured":"Pietrantonio, F. et al. INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC). J. Clin. Oncol. 41, 358 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72059_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamaoncol.2025.0522","volume":"11","author":"Z Peng","year":"2025","unstructured":"Peng, Z. et al. Atezolizumab and trastuzumab plus chemotherapy for ERBB2-positive locally advanced resectable gastric cancer. JAMA Oncol. 11, 619\u2013624 (2025).","journal-title":"JAMA Oncol."},{"key":"72059_CR12","unstructured":"Epstein-Barr virus and Kaposi\u2019s sarcoma herpesvirus\/human herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans. 70, 1\u2013492 (1997)."},{"key":"72059_CR13","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","DOI":"10.1038\/nature13480"},{"key":"72059_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","volume":"46","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku, A., Kunita, A. & Fukayama, M. Update on Epstein-Barr virus and gastric cancer (review). Int. J. Oncol. 46, 1421\u20131434 (2015).","journal-title":"Int. J. Oncol."},{"key":"72059_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.783695","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients. Front. Immunol. 13, 783695 (2022).","journal-title":"Front. Immunol."},{"key":"72059_CR16","doi-asserted-by":"publisher","first-page":"e1003341","DOI":"10.1371\/journal.ppat.1003341","volume":"9","author":"MJ Strong","year":"2013","unstructured":"Strong, M. J. et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog. 9, e1003341 (2013).","journal-title":"PLoS Pathog."},{"key":"72059_CR17","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania, B., Kenney, S. C. & Raab-Traub, N. Epstein-Barr virus: biology and clinical disease. Cell 185, 3652\u20133670 (2022).","journal-title":"Cell"},{"key":"72059_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","volume":"8","author":"M-Z Qiu","year":"2023","unstructured":"Qiu, M.-Z. et al. Dynamic single-cell mapping unveils Epstein\u2012Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal. Transduct. Target. Ther. 8, 370 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"72059_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24, 1449\u20131458 (2018).","journal-title":"Nat. Med."},{"key":"72059_CR20","first-page":"5006","volume":"11","author":"YT Sun","year":"2021","unstructured":"Sun, Y. T. et al. PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. Am. J. Cancer Res. 11, 5006\u20135015 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"72059_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"F Wang","year":"2019","unstructured":"Wang, F. et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody, in phase Ib\/II clinical trial NCT02915432. Ann. Oncol. 30, 1479\u20131486 (2019).","journal-title":"Ann. Oncol."},{"key":"72059_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40425-019-0514-3","volume":"7","author":"S Mishima","year":"2019","unstructured":"Mishima, S. et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J. Immunother. Cancer 7, 24 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"72059_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0000000000000316","volume":"43","author":"T Xie","year":"2020","unstructured":"Xie, T. et al. Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. J. Immunother. 43, 139\u2013144 (2020).","journal-title":"J. Immunother."},{"key":"72059_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937434","volume":"12","author":"MZ Qiu","year":"2020","unstructured":"Qiu, M. Z. et al. Observational cohort study of clinical outcome in Epstein-Barr virus-associated gastric cancer patients. Ther. Adv. Med. Oncol. 12, 1758835920937434 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"72059_CR25","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-20-0075","volume":"26","author":"Y Kubota","year":"2020","unstructured":"Kubota, Y. et al. The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer. Clin. Cancer Res. 26, 3784\u20133790 (2020).","journal-title":"Clin. Cancer Res."},{"key":"72059_CR26","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","volume":"31","author":"K Copied TextX Shitara","year":"2025","unstructured":"Copied TextX Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nat. Med. 31, 1519\u20131530 (2025).","journal-title":"Nat. Med."},{"key":"72059_CR27","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.annonc.2021.05.803","volume":"32","author":"K Shitara","year":"2021","unstructured":"Shitara, K. et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann. Oncol. 32, 1127\u20131136 (2021).","journal-title":"Ann. Oncol."},{"key":"72059_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2025","unstructured":"Li, C. et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J. Clin. Oncol. 43, 464\u2013474 (2025).","journal-title":"J. Clin. Oncol."},{"key":"72059_CR29","first-page":"e16091","volume":"40","author":"H Guo","year":"2022","unstructured":"Guo, H. et al. Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: a single-arm open-label phase II trial. Front. Oncol. 40, e16091 (2022).","journal-title":"Front. Oncol."},{"key":"72059_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen, S. et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 Trial. J. Clin. Oncol. 42, 410\u2013420 (2024).","journal-title":"J. Clin. Oncol."},{"key":"72059_CR31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00595-024-02829-7","volume":"54","author":"F Chen","year":"2024","unstructured":"Chen, F., Xian, J. & Huo, J. Prognostic significance of a pathological response in metastatic lymph nodes of patients with gastric cancer who underwent neoadjuvant chemotherapy followed by surgery. Surg. Today 54, 1255\u20131264 (2024).","journal-title":"Surg. Today"},{"key":"72059_CR32","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1097\/JS9.0000000000001626","volume":"110","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Finding the minimum number of retrieved lymph nodes and negative lymph nodes in gastric cancer surgery: a real-world study. Int. J. Surg. 110, 5574\u20135584 (2024).","journal-title":"Int. J. Surg."},{"key":"72059_CR33","doi-asserted-by":"publisher","first-page":"e004080","DOI":"10.1136\/jitc-2021-004080","volume":"10","author":"Y Bai","year":"2022","unstructured":"Bai, Y. et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. J. Immunother. Cancer 10, e004080 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"72059_CR34","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1016\/j.cell.2024.06.021","volume":"187","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. Assembly and activation of EBV latent membrane protein 1. Cell 187, 4996\u20135009.e14 (2024).","journal-title":"Cell"},{"key":"72059_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi, X. W. et al. PD-L1 is upregulated by EBV-driven LMP1 through the NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J. Hematol. Oncol. 9, 109 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"72059_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28479-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat. Commun. 13, 866 (2022).","journal-title":"Nat. Commun."},{"key":"72059_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","volume":"8","author":"MZ Qiu","year":"2023","unstructured":"Qiu, M. Z. et al. Dynamic single-cell mapping unveils Epstein\u2012Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal Transduct. Target Ther. 8, 370 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"72059_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 1081\u20131092 (2025).","journal-title":"Lancet Oncol."},{"key":"72059_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","volume":"17","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial. J. Hematol. Oncol. 17, 17 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"72059_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang, Y. K. et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol. Hepatol. 9, 705\u2013717 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"72059_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844142","volume":"13","author":"B Lv","year":"2022","unstructured":"Lv, B. et al. Immunotherapy: reshape the tumor immune microenvironment. Front. Immunol. 13, 844142 (2022).","journal-title":"Front. Immunol."},{"key":"72059_CR42","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"72059_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","volume":"9","author":"A Durgeau","year":"2018","unstructured":"Durgeau, A., Virk, Y., Corgnac, S. & Mami-Chouaib, F. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front. Immunol. 9, 14 (2018).","journal-title":"Front. Immunol."},{"key":"72059_CR44","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 310, 2191\u20132194 (2013).","DOI":"10.1001\/jama.2013.281053"},{"key":"72059_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205\u2013213 (2004).","journal-title":"Ann. Surg."},{"key":"72059_CR46","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker, K. et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98, 1521\u20131530 (2003).","journal-title":"Cancer"},{"key":"72059_CR47","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","volume":"253","author":"K Becker","year":"2011","unstructured":"Becker, K. et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann. Surg. 253, 934\u2013939 (2011).","journal-title":"Ann. Surg."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72059-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72059-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72059-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:02:25Z","timestamp":1782777745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72059-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72059"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72059-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5649"}}